Biontech's Takeover of Curevac: Boosting the Fight Against Cancer with mRNA Technology
Biotech company BioNTech set to purchase rival CureVac, a German pharmaceutical firm
In a significant move, Biontech, a leading pharmaceutical company based in Mainz, plans to swoop up its German rival, Curevac, headquartered in Tübingen. The primary goal? Expanding Biontech's prowess in the realm of mRNA-based cancer treatments. This multibillion-dollar deal has garnered the support of the German government.
Biontech, with its sights set on a bold future, aims to acquire all shares of Curevac. This merger would further enhance Biontech's know-how in the creation of mRNA-based cancer therapies.
The deal, expected to be worth billions, will see Biontech exchanging each Curevac share for its American Depositary Shares (ADS). Both companies are plugged into the US technology exchange Nasdaq.
Valuing Curevac at roughly $1.25 billion (€1.08 billion), the offer has Curevac shareholders expected to hold between 4 and 6% of Biontech post-acquisition. If all goes according to plan, the deal is slated to close by the end of 2025, subject to regulatory approvals.
Biontech appears well on its way to completing the acquisition. Nearly 37% of Curevac shares are in the hands of shareholders who have signed agreements to tender their shares, contingent upon certain conditions, including Dievini, a biotech founded by SAP co-founder Dietmar Hopp. The offer is subject to a minimum acceptance threshold of 80%.
The German government has expressed a positive stance toward the deal, with KfW, which holds 13.32% of Curevac on behalf of the Federal Republic of Germany, expected to support the transaction. With these agreements in place, Biontech would already control a staggering 50.08% of Curevac shares.
Ugur Sahin, CEO and co-founder of Biontech, described this transaction as "another building block in Biontech's oncology strategy and an investment in the future of cancer medicine." Biontech's reputation soared with its mRNA-based COVID-19 vaccine, and it's now focusing on cancer immunotherapy, with plans to submit its first US approval application for a next-generation chemotherapy against ovarian cancer by the end of the year.
Curevac, a trailblazer in mRNA technology, has been researching it for years. Though once hailed as a beacon of hope in the development of a vaccine against the virus, Curevac withdrew its first vaccine candidate from the approval process due to relatively low efficacy, leading to patent disputes with Biontech. Recently, Curevac has been downsizing and focusing on research.
Alexander Zehnder, Curevac's CEO, expressed his excitement for the merger, stating, "This transaction is far more than just a business step for me. Both companies have been pursuing similar goals for over two decades, often tackling challenges from different angles." He aims to unite their efforts under one roof, with Curevac’s Tübingen research and development site set to remain.
This merger denotes a strategic move toward enhancing mRNA-based cancer treatments and solidifying Biontech's position in the oncology market.
- Dietmar Hopp
- Curevac
- Biontech
- Mergers and Acquisitions
Enrichment Data:
Strategic Significance of the Merger
- Strengthening Research and Development: The merger aims to bolster the combined companies' research, development, manufacturing, and commercialization of experimental mRNA-based cancer immunotherapies by combining complementary scientific capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing.
- Expanding Oncology Strategy: This transaction marks a significant stride in Biontech's oncology strategy, which focuses on two pan-tumor programs and mRNA-based cancer immunotherapy candidates.
- Patent Dispute Resolution: The deal could also resolve global patent disputes between Biontech and CureVac, which are pending in Germany, the UK, and the US.
- Integration of Assets: CureVac’s state-of-the-art research and manufacturing site in Tübingen will be integrated into Biontech, enhancing its capabilities in mRNA technology.
Potential Impact on mRNA-Based Cancer Therapies
- Accelerated Development: The combined resources and expertise are expected to accelerate the development of innovative mRNA-based cancer treatments, potentially leading to new standards of care for various types of cancer.
- Complementary Technologies: The integration of CureVac's technologies with Biontech's capabilities could lead to more effective and transformative cancer therapies by leveraging the strengths of both companies.
- Long-term Value Creation: The all-stock acquisition is designed to create long-term value for both companies' shareholders, driven by their focus on mRNA innovation and shared vision for advancing cancer medicine.
- This move towards a merger between Biontech and Curevac, offering valuable insights into the Community policy and Employment policy of both companies, is driven by the strategic significance of consolidating their resources in mRNA-based cancer immunotherapy research and development.
- The integration of CureVac's cutting-edge mRNA technology with Biontech's expertise in mRNA design, delivery formulations, and manufacturing, promises to revolutionize Employment policy within the technology sector as the combined entity continues to innovate and progress in the realm of mRNA-based cancer therapies.
